[Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)

September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET)

Up to $5,000,000 per project; multi-year funding; milestone-based payments.

Supports IND-enabling studies and early-phase clinical trials for novel drugs and devices targeting Alzheimer’s disease and related dementias.

Anti-amyloid and cholinesterase inhibitor proposals are not eligible.

--- ## Description This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for pharmacological interventions and devices targeting Alzheimer’s disease and related dementias. The focus is on diverse drug mechanisms related to the biology of aging and emerging therapeutic areas, such as epigenetics, inflammation, mitochondrial function, neuroprotection, proteostasis, synaptic activity, and vascular function. Both novel and repurposed drugs, natural products, and devices are eligible, provided there is strong biological rationale and preliminary data. Anti-amyloid and cholinesterase inhibitor projects are specifically excluded. Combination therapies and projects with innovative intellectual property strategies are encouraged. Proposals should include biomarker-based outcomes and involve multidisciplinary teams. --- ## Due Dates - September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET) - Invited Full Proposal: Date to be determined --- ## Funding Amount - Maximum award: Up to $5,000,000 per project - Funding is milestone-based and negotiated according to project scope and stage - Multi-year support is typical - Only direct costs are allowed; no indirect/overhead costs are permitted - Co-funding from other agencies or investors is encouraged for projects requiring additional resources --- ## Eligibility - Open to researchers and clinicians worldwide at: - Academic medical centers, universities, and nonprofits - Biotechnology companies (existing or new startups) - Industry partnerships are strongly encouraged - Funding is provided through mission-related investments requiring return on investment based on milestones - Applicants may submit one LOI and one full proposal per cycle; institutions may have multiple applicants for different projects --- ## Application Process 1. **Letter of Intent (LOI):** - Submit via the [ADDF Funding Portal](https://addf.fluxx.io/) - Includes project summary, specific aims, and key supporting data (each 300 words max) - Applicants notified of LOI outcome within 2–3 weeks after deadline 2. **Full Proposal:** - By invitation only, following LOI approval - Must be submitted in the same cycle as LOI (effective 2026) - Requires detailed project narrative, budget, biosketches, and (for biotech companies) a business packet - Proposals reviewed by external scientific and business experts; funding decisions in 3–4 months post submission 3. **Required Documentation:** - Project narrative (background, rationale, supporting data, plan, methods, team, IP, other support, references) - Budget (Excel format, direct costs only) - Biosketches (NIH format, 5 pages max) - Additional forms as applicable (e.g., compound report card, animal/human subjects questionnaires) - For biotech companies: business packet (business plan, financials, IP summary, etc.) 4. **Additional Notes:** - All clinical trials funded must register and report results on [ClinicalTrials.gov](https://register.clinicaltrials.gov/) - Only one LOI and one full proposal per applicant per cycle --- ## Additional Information - Projects must focus on mechanisms other than anti-amyloid or cholinesterase inhibition - Only direct costs are allowed; no indirect, overhead, or capital equipment costs - Funding is provided as mission-related investments, not traditional grants, and is structured to allow ADDF to recoup investment based on project success - Investigators seeking follow-on funding should contact ADDF staff three months before the end of their funding period --- ## External Links - [RFP Details and Application Page](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-rfp) - [Application Instructions](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/application-instructions) - [Funding Policies](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies) - [ADDF Funding Portal](https://addf.fluxx.io/) - [Our Research Strategy](https://www.alzdiscovery.org/research-and-grants/our-research-strategy) --- ## Contact Information | Contact | Details | |------------------------|-----------------------------------------------------------| | General Inquiries | [info@alzdiscovery.org](mailto:info@alzdiscovery.org) | | Grants Team | [grants@alzdiscovery.org](mailto:grants@alzdiscovery.org) | | Phone | 212.901.8000 | | Contact Form | [Contact ADDF](https://www.alzdiscovery.org/contact-us) |

Drug Development RFP

Sign in to see full grant listing